TECENTRIQ® (atezolizumab): A new important identified risk – immune-related myositis


User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive



TECENTRIQ® (atezolizumab) has been associated with the risk of immune-related myositis.

In a comprehensive analysis that was performed across the TECENTRIQ® programme, cases of immune-related myositis including biopsy-confirmed cases have been identified in patients who received atezolizumab.  


It is recommended that:


NPRA has approved a Direct Healthcare Professional Communication (DHPC) letter issued by Roche (M) Sdn. Bhd. to highlight this safety issue. For further information, please contact your local sales person for a copy of the DHPC.